Profile data is unavailable for this security.
About the company
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
- Revenue in USD (TTM)72.12k
- Net income in USD-5.08m
- Incorporated2023
- Employees--
- LocationSilo Pharma Inc677 N Washington BlvdSARASOTA 34236United StatesUSA
- Websitehttps://silopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.25m | 0.00 | -- | 12.93 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.25m | 4.00 | -- | 0.1864 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.70m | 7.00 | -- | 0.5882 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 3.83m | 8.00 | -- | 0.119 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 3.83m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.89m | -- | -- | 0.6099 | -- | 53.92 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.91m | 3.00 | -- | 0.5575 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.93m | 32.00 | -- | -- | -- | 1.18 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.94m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 4.00m | 17.00 | -- | 0.5594 | -- | 1.19 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.01m | 3.00 | -- | 0.1746 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.15m | 8.00 | -- | 0.3248 | -- | 8.49 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.16m | 21.00 | -- | 16.39 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| Weed Inc | 0.00 | -755.25k | 4.38m | 2.00 | -- | -- | -- | -- | -0.0058 | -0.0058 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -133.78 | -117.17 | -- | -371.94 | -- | -- | -- | -- | -- | -22.55 | -- | -- | -- | -- | -1,518.25 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Silo Pharma Inc's reporting currency: US Dollar USD
11.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 30 Sep 2025 | 952.38k | 7.15% |
| AdvisorShares Investments LLCas of 30 Sep 2025 | 364.88k | 2.74% |
| Virtu Americas LLCas of 30 Sep 2025 | 107.79k | 0.81% |
| Geode Capital Management LLCas of 30 Sep 2025 | 39.60k | 0.30% |
| Jane Street Capital LLCas of 30 Sep 2025 | 16.77k | 0.13% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 16.47k | 0.12% |
| StoneX Group, Inc. (Investment Management)as of 30 Sep 2025 | 13.43k | 0.10% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.10k | 0.10% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 12.50k | 0.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.22k | 0.08% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
